RICHMOND, British Columbia, July 3, 2008 (PRIME NEWSWIRE) -- BioCurex Inc. (OTCBB:BOCX) is aware of the recent trading activity in the company's stock and notes that there has been no material change in the business of the Company to support this activity.
The recent press releases document the significant progress that BioCurex is achieving both in the scientific arena and in the commercialization of its valuable technology. Thus, it is Management's opinion that the recent market activity is disconnected from the Company's fundamentals in terms of cash position, technology value, licensing agreements and recently announced commercialization initiatives.
While the Company is unaware of the reasons for the unexpected market activity, it would like to remind its shareholders and prospective investors that the only information to be relied upon regarding BioCurex is information directly released by the Company or contained in public information such as its SEC filings available at http://www.sec.gov. (http://sec.gov/cgi-bin/browse-edgar?company=whispering+oaks&CIK=&filenum=&State=&SIC=&owner=include&action=getcompany)
BioCurex will continue to update the public and its shareholders on its progress.
About BioCurex:
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.
BioCurex has signed licensing agreements for its cancer detection blood tests with Abbott Laboratories and with Inverness Medical Innovations (for further information on these agreements see: http://sec.gov/Archives/edgar/data/1092562/000100487808000117/sb2amnd4s1april08.txt).
The cancer marker RECAF(tm) has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others.
To read more about the Company, please visit the News section in our web site (www.biocurex.com).
Note: The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.